Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bristol-Myers Squibb Looks To Feed Oncology Pipeline With New Protein Class

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Discovery and development deal could be worth up to $1.3 billion for Waltham, Mass.-based Adnexus.

You may also be interested in...



Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business

Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.

Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business

Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.

FDA Grants Satraplatin Priority Review

GPC Biotech completed rolling NDA in February; action date on novel platinum-based oncologic is Aug. 15.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Final ICH Guide Supports Nonclinical Development Of Gene Therapy Products

NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others

Canadian Action On Rare Disease Is A ‘Step Forward,’ Says Industry

Three Firms Sign Up With MPP For Long-Acting Cabotegravir

See All
UsernamePublicRestriction

Register

PS065679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By